{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:50:24Z","timestamp":1770040224344,"version":"3.49.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,15]]},"DOI":"10.1093\/jnci\/djj053","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T08:57:49Z","timestamp":1139907469000},"page":"273-284","source":"Crossref","is-referenced-by-count":86,"title":["Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia"],"prefix":"10.1093","volume":"98","author":[{"given":"Jean-Luc","family":"Canon","sequence":"first","affiliation":[]},{"given":"Johan","family":"Vansteenkiste","sequence":"additional","affiliation":[]},{"given":"Gy\u00f6rgy","family":"Bodoky","sequence":"additional","affiliation":[]},{"given":"M. Victoria","family":"Mateos","sequence":"additional","affiliation":[]},{"given":"Laurent","family":"Bastit","sequence":"additional","affiliation":[]},{"given":"Irene","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Greg","family":"Rossi","sequence":"additional","affiliation":[]},{"given":"Rafael G.","family":"Amado","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2006,2,15]]},"reference":[{"key":"key\n\t\t\t\t20171012225401_BIB1","doi-asserted-by":"crossref","unstructured":"Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst1999 ; 91 : 1616 \u201334.","DOI":"10.1093\/jnci\/91.19.1616"},{"key":"key\n\t\t\t\t20171012225401_BIB2","doi-asserted-by":"crossref","unstructured":"Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer2003 ; 39 : 2026 \u201334.","DOI":"10.1016\/S0959-8049(03)00456-8"},{"key":"key\n\t\t\t\t20171012225401_BIB3","doi-asserted-by":"crossref","unstructured":"Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst2002 ; 94 : 1211 \u201320.","DOI":"10.1093\/jnci\/94.16.1211"},{"key":"key\n\t\t\t\t20171012225401_BIB4","doi-asserted-by":"crossref","unstructured":"Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol2003 ; 122 : 394 \u2013403.","DOI":"10.1046\/j.1365-2141.2003.04448.x"},{"key":"key\n\t\t\t\t20171012225401_BIB5","doi-asserted-by":"crossref","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol2001 ; 19 : 2865 \u201374.","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"key\n\t\t\t\t20171012225401_BIB6","doi-asserted-by":"crossref","unstructured":"Osterborg A. New erythropoietic proteins: rationale and clinical data. Semin Oncol2004 ; 31 (3 Suppl 8): 12 \u20138.","DOI":"10.1053\/j.seminoncol.2004.04.005"},{"key":"key\n\t\t\t\t20171012225401_BIB7","doi-asserted-by":"crossref","unstructured":"Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol2005 ; 23 : 2606 \u201317.","DOI":"10.1200\/JCO.2004.10.020"},{"key":"key\n\t\t\t\t20171012225401_BIB8","doi-asserted-by":"crossref","unstructured":"Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol2005 ; 23 : 2597 \u2013605.","DOI":"10.1200\/JCO.2004.12.027"},{"key":"key\n\t\t\t\t20171012225401_BIB9","doi-asserted-by":"crossref","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol2001 ; 19 : 2875 \u201382.","DOI":"10.1200\/JCO.2001.19.11.2875"},{"key":"key\n\t\t\t\t20171012225401_BIB10","doi-asserted-by":"crossref","unstructured":"Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer2002 ; 87 : 1341 \u201353.","DOI":"10.1038\/sj.bjc.6600657"},{"key":"key\n\t\t\t\t20171012225401_BIB11","unstructured":"Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol1997 ; 34 (3 Suppl 2): 20 \u20136."},{"key":"key\n\t\t\t\t20171012225401_BIB12","doi-asserted-by":"crossref","unstructured":"Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol2003 ; 14 : 511 \u20139.","DOI":"10.1093\/annonc\/mdg167"},{"key":"key\n\t\t\t\t20171012225401_BIB13","doi-asserted-by":"crossref","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol1998 ; 16 : 3412 \u201325.","DOI":"10.1200\/JCO.1998.16.10.3412"},{"key":"key\n\t\t\t\t20171012225401_BIB14","doi-asserted-by":"crossref","unstructured":"Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol2003 ; 31 : 290 \u20139.","DOI":"10.1016\/S0301-472X(03)00006-7"},{"key":"key\n\t\t\t\t20171012225401_BIB15","doi-asserted-by":"crossref","unstructured":"Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer2005 ; 41 : 1140 \u20139.","DOI":"10.1016\/j.ejca.2005.01.021"},{"key":"key\n\t\t\t\t20171012225401_BIB16","unstructured":"Aranesp (darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen Inc., 2005 . Available at: http:\/\/www.aranesp.com\/pdf\/aranesp_PI.pdf ."},{"key":"key\n\t\t\t\t20171012225401_BIB17","unstructured":"Aranesp (darbepoetin alfa) [summary of product characteristics]. Breda (The Netherlands). Amgen Europe B.V., 2005. Available at: http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPAR\/aranesp\/H-332-PI-en.pdf ."},{"key":"key\n\t\t\t\t20171012225401_BIB18","unstructured":"Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park)2002 ; 16 (10 Suppl 11): 23 \u20139."},{"key":"key\n\t\t\t\t20171012225401_BIB19","doi-asserted-by":"crossref","unstructured":"Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer2002 ; 87 : 268 \u201376.","DOI":"10.1038\/sj.bjc.6600465"},{"key":"key\n\t\t\t\t20171012225401_BIB20","doi-asserted-by":"crossref","unstructured":"Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist2004 ; 9 : 696 \u2013707.","DOI":"10.1634\/theoncologist.9-6-696"},{"key":"key\n\t\t\t\t20171012225401_BIB21","unstructured":"Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol2003 ; 1 : 131 \u20138."},{"key":"key\n\t\t\t\t20171012225401_BIB22","doi-asserted-by":"crossref","unstructured":"Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm2005 ; 62 : 54 \u201362.","DOI":"10.1093\/ajhp\/62.1.54"},{"key":"key\n\t\t\t\t20171012225401_BIB23","doi-asserted-by":"crossref","unstructured":"Canon J-L, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, et al. Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy [abstract 0471]. Haematologica2005 ; 90 (S2): 190 .","DOI":"10.1200\/jco.2005.23.16_suppl.lba8284"},{"key":"key\n\t\t\t\t20171012225401_BIB24","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer2004 ; 100 : 859 \u201368.","DOI":"10.1002\/cncr.11954"},{"key":"key\n\t\t\t\t20171012225401_BIB25","unstructured":"Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC. Clinical trial simulation of a 200-\u03bcg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Williston Park)2002 ; 16 (10 Suppl 11): 37 \u201344."},{"key":"key\n\t\t\t\t20171012225401_BIB26","doi-asserted-by":"crossref","unstructured":"Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther2003 ; 25 : 2781 \u201396.","DOI":"10.1016\/S0149-2918(03)80333-8"},{"key":"key\n\t\t\t\t20171012225401_BIB27","unstructured":"Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol1992 ; 19 (3 Suppl 8): 29 \u201335."},{"key":"key\n\t\t\t\t20171012225401_BIB28","unstructured":"Rodgers GM, editor. Guidelines for supportive care: cancer and treatment-related anemia. Version 2. 2005 ed. National Comprehensive Cancer Network. Available at: http:\/\/www.nccn.org\/physician_gls\/index.html . [Last accessed: December 2, 2005 .]"},{"key":"key\n\t\t\t\t20171012225401_BIB29","doi-asserted-by":"crossref","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood2002 ; 100 : 2303 \u201320.","DOI":"10.1182\/blood-2002-06-1767"},{"key":"key\n\t\t\t\t20171012225401_BIB30","doi-asserted-by":"crossref","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol2002 ; 20 : 4083 \u2013107.","DOI":"10.1200\/JCO.2002.07.177"},{"key":"key\n\t\t\t\t20171012225401_BIB31","doi-asserted-by":"crossref","unstructured":"Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer2004 ; 40 : 2201 \u201316.","DOI":"10.1016\/j.ejca.2004.07.015"},{"key":"key\n\t\t\t\t20171012225401_BIB32","unstructured":"Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol1997 ; 34 (3 Suppl 2): 13 \u20139."},{"key":"key\n\t\t\t\t20171012225401_BIB33","doi-asserted-by":"crossref","unstructured":"Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage2002 ; 24 : 547 \u201361.","DOI":"10.1016\/S0885-3924(02)00529-8"},{"key":"key\n\t\t\t\t20171012225401_BIB34","doi-asserted-by":"crossref","unstructured":"Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst2005 ; 97 : 489 \u201398.","DOI":"10.1093\/jnci\/dji087"},{"key":"key\n\t\t\t\t20171012225401_BIB35","doi-asserted-by":"crossref","unstructured":"Naumova EN, Must A, Laird NM. Tutorial in biostatistics: evaluating the impact of \u2018critical periods\u2019 in longitudinal studies of growth using piecewise mixed effects models. Int J Epidemiol2001 ; 30 : 1332 \u201341.","DOI":"10.1093\/ije\/30.6.1332"},{"key":"key\n\t\t\t\t20171012225401_BIB36","doi-asserted-by":"crossref","unstructured":"Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards for Reporting of Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA2001 ; 285 : 1987 \u201391.","DOI":"10.1001\/jama.285.15.1987"},{"key":"key\n\t\t\t\t20171012225401_BIB37","doi-asserted-by":"crossref","unstructured":"Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis2002 ; 40 : 110 \u20138.","DOI":"10.1053\/ajkd.2002.33919"},{"key":"key\n\t\t\t\t20171012225401_BIB38","doi-asserted-by":"crossref","unstructured":"Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int2002 ; 62 : 2167 \u201375.","DOI":"10.1046\/j.1523-1755.2002.00657.x"},{"key":"key\n\t\t\t\t20171012225401_BIB39","doi-asserted-by":"crossref","unstructured":"Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol2003 ; 122 : 386 \u201393.","DOI":"10.1046\/j.1365-2141.2003.04439.x"},{"key":"key\n\t\t\t\t20171012225401_BIB40","doi-asserted-by":"crossref","unstructured":"Glaspy J, Berg R, Tomita D, Rossi G, Vadhan-Raj S. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (weekly) in patients with chemotherapy-induced anemia (CIA) [abstract 8125]. J Clin Oncol2005 ; 23 : 16S .","DOI":"10.1200\/jco.2005.23.16_suppl.8125"},{"key":"key\n\t\t\t\t20171012225401_BIB41","doi-asserted-by":"crossref","unstructured":"Kotasek D, Canon J-L, San Miguel J, Hedenus M, Hendricks L, Rossi G, et al. Correction maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial [abstract 1636]. Blood2004 ; 104 : 455a .","DOI":"10.1182\/blood.V104.11.1636.1636"},{"key":"key\n\t\t\t\t20171012225401_BIB42","unstructured":"ICH Guideline E9. Statistical principles for clinical trials [in force September 1998]. Fed Regist1998 ; 63 (179) 49583 ."},{"key":"key\n\t\t\t\t20171012225401_BIB43","unstructured":"Procrit (Epoetin alfa) [product insert]. Raritan, NJ: Ortho Biotech Products, L.P., 2005 . Available at: http:\/\/www.procrit.com\/common\/prescribing_information\/PROCRIT\/PDF\/ProcritBooklet.pdf ."},{"key":"key\n\t\t\t\t20171012225401_BIB44","unstructured":"U.S. Food and Drug Administration. Oncology Drugs Advisory Committee, May 4, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/4037b2.htm . [Last accessed: December 2, 2005 .]"},{"key":"key\n\t\t\t\t20171012225401_BIB45","doi-asserted-by":"crossref","unstructured":"Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol2003 ; 4 : 459 \u201360.","DOI":"10.1016\/S1470-2045(03)01163-X"},{"key":"key\n\t\t\t\t20171012225401_BIB46","doi-asserted-by":"crossref","unstructured":"Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet2003 ; 362 : 1255 \u201360.","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"key\n\t\t\t\t20171012225401_BIB47","unstructured":"Amgen Inc. Aranesp (darbepoetin alfa) safety: Oncologic Drugs Advisory Committee, May 4, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/4037b2.htm . [Last accessed: December 2, 2005 .]"},{"key":"key\n\t\t\t\t20171012225401_BIB48","doi-asserted-by":"crossref","unstructured":"Hedenus M, Canon J-L, Kotasek D, Lillie T, Hendricks L, Yao B, et al. Effects of does adjustment rules on safety during erythropoietic therapy: a retrospective analysis of darbepoetin alfa administered either every 3 weeks or weekly [abstract 3376]. Blood2005 ; 106 : 3376 .","DOI":"10.1182\/blood.V106.11.3376.3376"},{"key":"key\n\t\t\t\t20171012225401_BIB49","doi-asserted-by":"crossref","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer2004 ; 40 : 2293 \u2013306.","DOI":"10.1016\/j.ejca.2004.06.019"},{"key":"key\n\t\t\t\t20171012225401_BIB50","doi-asserted-by":"crossref","unstructured":"Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, et al. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med2004 ; 116 : 28 \u201334.","DOI":"10.1016\/j.amjmed.2003.06.004"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/98\/4\/273\/7688294\/djj053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T21:43:49Z","timestamp":1627076629000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jnci\/article\/98\/4\/273\/2521973\/Randomized-DoubleBlind-ActiveControlled-Trial-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,15]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,2,15]]},"published-print":{"date-parts":[[2006,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djj053","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2,15]]},"published":{"date-parts":[[2006,2,15]]}}}